πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 763 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 10981866

Chemical conjugates of Evans Blue derivatives and their use as radiotherapy and imaging ag

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10980848

Antimicrobial therapy

The Regents of the University of California Β· Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10980868

VEGFR-2 targeting immunotherapy approach

Vaximm AG Β· Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10983128

CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy

Providence Health & Services Β· Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10953047

Processes for production of tumor infiltrating lymphocytes and uses of same in immunothera

Iovance Biotherapeutics, Inc. Β· Granted Tue Mar 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10953046

Processes for production of tumor infiltrating lymphocytes and uses of same in immunothera

Iovance Biotherapeutics, Inc. Β· Granted Tue Mar 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10954304

Neutralizing antibodies to the Ξ±vΞ²8 integrin complex for immunotherapy

The Regents of the University of California Β· Granted Tue Mar 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10946045

Processes for production of tumor infiltrating lymphocytes and uses of same in immunothera

Iovance Biotherapeutics, Inc. Β· Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10946044

Processes for production of tumor infiltrating lymphocytes and uses of same in immunothera

Iovance Biotherapeutics, Inc. Β· Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10946080

Compositions and methods for combination therapy with dengue virus and dendritic cells

PrimeVax Immuno-Oncology Β· Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10946000

Method for treating cancer with combination therapy

RedHill Biopharma Ltd. Β· Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10940160

Biomarkers for predicting responsiveness to decitabine therapy

THE REGENTS OF THE UNIVERSITY OF MICHIGAN Β· Granted Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10940133

Methods of providing solriamfetol therapy to subjects with impaired renal function

Jazz Pharmaceuticals Ireland Limited Β· Granted Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10933094

Processes for production of tumor infiltrating lymphocytes and uses of same in immunothera

Iovance Biotherapeutics, Inc. Β· Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10935554

Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specifi

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10933076

Crocin-sorafenib combination therapy for liver cancer

UNITED ARAB EMIRATES UNIVERSITY Β· Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10934550

Immunotherapy of cancer

Phio Pharmaceuticals Corp. Β· Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10934334

Peptides for angiogenic therapy

The Regents of the University of California Β· Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10925977

Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and ap

The Board of Regents of the University of Texas System Β· Granted Tue Feb 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10925928

Method for treating chemotherapy-induced male infertility

The Board of Regents of the University of Texas System Β· Granted Tue Feb 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10918666

Processes for production of tumor infiltrating lymphocytes and uses of same in immunothera

Iovance Biotherapeutics, Inc. Β· Granted Tue Feb 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10912797

Tumor infiltrating lymphocytes and methods of therapy

THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF TECHNOLOGY TRANSFERβ€”NATIONAL INSTITUTES OF HEALTH Β· Granted Tue Feb 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10905692

Combination therapy for treating malignancies

Agios Pharmaceuticals, Inc. Β· Granted Tue Feb 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10905752

VEGFR-2 targeting DNA vaccine for combination therapy

Vaximm AG Β· Granted Tue Feb 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted